News | February 26, 2015

Cherenkov Effect Improves Radiation Therapy for Cancer Patients

Researchers say blue light can help calculate dosimetry of X-ray photons, protons and electrons

Cherenkov effect, radiation therapy, treatment planning, dosimetry

February 26, 2015 — Investigators from Dartmouth College’s Norris Cotton Cancer Center have discovered how the complex parts of the blue light known as the Cherenkov effect can be measured and used in dosimetry to make radiation therapies safer and more effective. Findings of the study, led by Brian W. Pogue, Ph.D., and Ph.D. candidates Adam K. Glaser and Rongxiao Zhang, were published in the journal Physics in Medicine and Biology.

"The beauty of using the light from the Cherenkov Effect for dosimetry is that it's the only current method that can reveal dosimetric information completely non-invasively in water or tissue," said Glaser.

Although the phenomenon has been constructively utilized for decades in high-energy particle and astrophysics, only recently has it been investigated during radiation therapy. In this study, investigators separately measured emissions of X-ray photons, protons and electrons, and they found widely varying utility.

Based on the findings of where dose correlates with Cherenkov emission, the Dartmouth team concluded that for X-ray photons, the light emission would be optimally suited for: narrow beam stereotactic radiation therapy and surgery validation studies; verification of dynamic intensity-modulated and volumetric modulated arc therapy treatment plans in water tanks; near mono-energetic sources (e.g., Co-60 and brachytherapy sources); and also for entrance and exit surface imaging dosimetry of both narrow and broad beams.

For electron use, Cherenkov emission was found to be suitable only for surface dosimetry applications. Finally, for proton dosimetry, there exists a fundamental lack of Cherenkov emission at the Bragg peak, making the technique of little use, although investigators say that post-irradiation detection of light emission from radioisotopes could prove to be useful.

"By detecting this light, we can pursue novel applications of Cherenkov light emission during radiation therapy to help clinicians improve the overall treatment outcome for patients," explained Pogue.

The collaborators intend to pursue further investigation at Norris Cotton Cancer Center to find other applications where this "free" light can be useful, such as continuing clinical trials in which the Cherenkov light from X-ray beams is imaged directly from a patient's tissue surface during radiation therapy.

For more information: www.cancer.dartmouth.edu

Related Content

The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | Radiation Oncology | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused
The drug, known as Avasopasem manganese, is made by Galera Therapeutics. It acts like a natural enzyme called superoxide dismutase and converts superoxide into hydrogen peroxide. Based on its ability to "mop up" damaging superoxide molecules, which are produced by radiation treatment, the drug is currently in clinical trials to test its ability to protect mucosal tissue from the side-effect of radiotherapy.

Getty Images

News | Radiation Therapy | May 19, 2021
May 19, 2021 — A small drug molecule that appears to protect normal tissue from the damaging effects of...